• Shandong Xinhua unit Shandong Zibo Xincat Pharma secured China marketing clearance for donepezil hydrochloride orally disintegrating tablets, 5 mg.
• National Medical Products Administration issued the drug registration certificate in September 2026.
• Product targets mild to severe Alzheimer’s symptoms, expanding Xinhua’s central nervous system portfolio.
• China public-hospital sales of donepezil preparations totaled about RMB 620 million in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260918-12337546), on September 18, 2026, and is solely responsible for the information contained therein.